{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T15:46:32Z","timestamp":1777218392591,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ck0106307h0003"],"award-info":[{"award-number":["22ck0106307h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["2023-J-03_1-A"],"award-info":[{"award-number":["2023-J-03_1-A"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The concept of oligometastases was first proposed to describe a disease state between localized cancer and extensive metastasis. After the emergence of variations in the definition of oligometastasis, in April 2020 the European Society for Radiotherapy and Oncology and the European Organization for Research and Treatment of Cancer defined oligometastases as the presence of one to five metastatic lesions that can be safely treated. However, the pathogenesis of oligometastases remains unknown, and it is uncertain which patients will benefit from metastasis-directed therapy. Breast cancer with oligometastases is generally managed with systemic therapy. Retrospective studies have suggested that the addition of metastasis-directed therapy, such as surgery, radiofrequency ablation and stereotactic body radiation therapy, may increase overall survival in breast cancer patients with oligometastases, but as yet there have been no prospective studies. Phase II trials of stereotactic body radiation therapy or fractionated irradiation for oligometastases of breast cancer have demonstrated impressive rates of local control and overall survival. Although the efficacy of stereotactic body radiation therapy in the SABR-COMET was largely anticipated, it is noteworthy that only 18% of the patient population had breast cancer. For this reason, various trials were planned or are being conducted globally to investigate the efficacy of metastasis-directed therapy for oligometastases of breast cancer. Metastasis-directed therapy for oligometastases has been shown to be effective, and stereotactic body radiation therapy and other therapies are commonly used internationally and are considered to be safe. However, the efficacy of metastasis-directed therapy for oligometastases has not yet been proven. The results of future clinical trials are thus eagerly awaited.<\/jats:p>","DOI":"10.1093\/jjco\/hyad077","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T07:31:22Z","timestamp":1688974282000},"page":"893-898","source":"Crossref","is-referenced-by-count":4,"title":["Metastasis-directed therapy for oligometastases in breast cancer"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8709-4972","authenticated-orcid":false,"given":"Toshiyuki","family":"Ishiba","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuno","family":"Nishibuchi","sequence":"additional","affiliation":[{"name":"Hiroshima University Graduate School of Biomedical & Health Sciences Department of Radiation Oncology, , Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumikata","family":"Hara","sequence":"additional","affiliation":[{"name":"The Cancer Institute Hospital of JFCR Breast Oncology Center, , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Shikama","sequence":"additional","affiliation":[{"name":"Juntendo University Department of Radiation Oncology, , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-5512","authenticated-orcid":false,"given":"Tadahiko","family":"Shien","sequence":"additional","affiliation":[{"name":"Okayama University Hospital Department of Breast and Endocrine Surgery, , Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center Department of Breast Oncology, , Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"key":"2023100417311838700_ref1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"2023100417311838700_ref2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/PPO.0000000000000436","article-title":"Radiation in the treatment of Oligometastatic and Oligoprogressive disease: rationale, recent data, and research questions","volume":"26","author":"Zayed","year":"2020","journal-title":"Cancer J"},{"key":"2023100417311838700_ref3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2023100417311838700_ref4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41416-019-0601-8","article-title":"Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy","volume":"121","author":"Beckham","year":"2019","journal-title":"Br J Cancer"},{"key":"2023100417311838700_ref5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"key":"2023100417311838700_ref6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"2023100417311838700_ref7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European organisation for research and treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023100417311838700_ref8","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3390\/cancers14082046","article-title":"The road to dissemination: the concept of Oligometastases and the barriers for widespread disease","volume":"14","author":"AlGhamdi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023100417311838700_ref9","doi-asserted-by":"crossref","first-page":"pkab010","DOI":"10.1093\/jncics\/pkab010","article-title":"Characterization of Oligometastatic disease in a real-world Nationwide cohort of 3447 patients with de novo metastatic breast cancer","volume":"5","author":"Steenbruggen","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"2023100417311838700_ref10","doi-asserted-by":"crossref","DOI":"10.1007\/s12282-023-01436-7","article-title":"Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)","volume":"30","author":"Imoto","year":"2023","journal-title":"Breast Cancer"},{"key":"2023100417311838700_ref11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12282-012-0347-0","article-title":"Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review","volume":"19","author":"Kobayashi","year":"2012","journal-title":"Breast Cancer"},{"key":"2023100417311838700_ref12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s12282-021-01240-1","article-title":"Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report","volume":"28","author":"Nagasaki","year":"2021","journal-title":"Breast Cancer"},{"key":"2023100417311838700_ref13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000516114","article-title":"St. Gallen\/Vienna 2021: a brief summary of the consensus discussion on customizing therapies for women with early breast cancer","volume":"16","author":"Thomssen","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"2023100417311838700_ref14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/COC.0000000000000169","article-title":"Definitive stereotactic body radiotherapy (SBRT) for Extracranial Oligometastases: an international survey of &gt;1000 radiation oncologists","volume":"40","author":"Lewis","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"2023100417311838700_ref15","first-page":"1441","article-title":"Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis","volume":"7","author":"Fan","year":"2015","journal-title":"J Thorac Dis"},{"key":"2023100417311838700_ref16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1010-7940(02)00331-7","article-title":"Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the international registry of lung metastases","volume":"22","author":"Friedel","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"2023100417311838700_ref17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cncr.11881","article-title":"Uncertain benefit from surgery in patients with lung metastases from breast carcinoma","volume":"100","author":"Planchard","year":"2004","journal-title":"Cancer"},{"key":"2023100417311838700_ref18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-007-9747-9","article-title":"Favourable long-term results after surgical removal of lung metastases of breast cancer","volume":"110","author":"Yoshimoto","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2023100417311838700_ref19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.athoracsur.2012.11.043","article-title":"Prolonged overall survival after pulmonary Metastasectomy in patients with breast cancer","volume":"95","author":"Meimarakis","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"2023100417311838700_ref20","doi-asserted-by":"crossref","first-page":"643383","DOI":"10.3389\/fonc.2021.643383","article-title":"Hepatectomy, RFA, and other liver directed therapies for treatment of breast cancer liver metastasis: a systematic review","volume":"11","author":"Rivera","year":"2021","journal-title":"Front Oncol"},{"key":"2023100417311838700_ref21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/01.sla.0000246847.02058.1b","article-title":"Is liver resection justified for patients with hepatic metastases from breast cancer?","volume":"244","author":"Adam","year":"2006","journal-title":"Ann Surg"},{"key":"2023100417311838700_ref22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.surg.2011.12.017","article-title":"Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome","volume":"151","author":"Abbott","year":"2012","journal-title":"Surgery"},{"key":"2023100417311838700_ref23","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.hpb.2016.05.014","article-title":"The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis","volume":"18","author":"Margonis","year":"2016","journal-title":"HPB (Oxford)"},{"key":"2023100417311838700_ref24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12094-019-02155-2","article-title":"Resection of liver metastases from breast cancer: a multicentre analysis","volume":"22","author":"He","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2023100417311838700_ref25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1148\/radiol.2533081968","article-title":"Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates","volume":"253","author":"Meloni","year":"2009","journal-title":"Radiology"},{"key":"2023100417311838700_ref26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hpb.12133","article-title":"A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver","volume":"15","author":"Ta\u015f\u00e7i","year":"2013","journal-title":"HPB (Oxford)"},{"key":"2023100417311838700_ref27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/02656736.2018.1488279","article-title":"Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer","volume":"35","author":"Bai","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"2023100417311838700_ref28","doi-asserted-by":"crossref","first-page":"651646","DOI":"10.3389\/fonc.2021.651646","article-title":"Efficacy and safety of radiofrequency ablation for breast cancer smaller than 2 cm: a systematic review and meta-analysis","volume":"11","author":"Xia","year":"2021","journal-title":"Front Oncol"},{"key":"2023100417311838700_ref29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"2023100417311838700_ref30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","article-title":"Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade","volume":"131","author":"Milano","year":"2019","journal-title":"Radiother Oncol"},{"key":"2023100417311838700_ref31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2020","journal-title":"Breast (Edinburgh)"},{"key":"2023100417311838700_ref32","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"2023100417311838700_ref33","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of Oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023100417311838700_ref34","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with Oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023100417311838700_ref35","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment with stereotactic ablative radiotherapy for up to 5 Oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial","volume":"8","author":"Olson","year":"2022","journal-title":"JAMA Oncol"},{"key":"2023100417311838700_ref36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncol"},{"key":"2023100417311838700_ref37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jjco\/hyv110","article-title":"Intensive vs. standard post-operative surveillance in high-risk breast cancer patients (INSPIRE): Japan clinical oncology group study JCOG1204","volume":"45","author":"Hojo","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2023100417311838700_ref38","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2023100417311838700_ref39","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"2023100417311838700_ref40","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023100417311838700_ref41","doi-asserted-by":"crossref","first-page":"e28650","DOI":"10.1371\/journal.pone.0028650","article-title":"MicroRNA expression characterizes oligometastasis(es)","volume":"6","author":"Lussier","year":"2011","journal-title":"PloS One"},{"key":"2023100417311838700_ref42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/10\/893\/51848961\/hyad077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/10\/893\/51848961\/hyad077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:32:00Z","timestamp":1696440720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/10\/893\/7221581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,8]]},"published-print":{"date-parts":[[2023,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad077","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,7,8]]}}}